Edward R Laws1, Angel M Morris, Nicholas Maartens. 1. Department of Neurosurgery, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908-0212, USA. el5g@virginia.edu
Abstract
OBJECTIVE: We developed a protocol for a clinical trial of postresection implantation of Gliadel wafers in patients with aggressive, relentlessly recurring pituitary adenomas and craniopharyngiomas. METHODS: Ten patients, nine with pituitary adenomas and one with a craniopharyngioma, underwent implantation of from two to eight Gliadel wafers. RESULTS: No obvious adverse reactions occurred. Death as a result of disease progression occurred in two patients with malignant adenomas. One patient died as a result of a stroke after undergoing five surgical procedures and prior radiotherapy. The seven living patients have been followed for 5 to 27 months (mean follow-up, 19 mo). Four patients have been free of recurrent or residual tumor, two have stable residual disease, and one has experienced tumor progression. CONCLUSION: The results of this study suggest a role for Gliadel implantation in patients with recurring aggressive pituitary adenomas and craniopharyngiomas.
OBJECTIVE: We developed a protocol for a clinical trial of postresection implantation of Gliadel wafers in patients with aggressive, relentlessly recurring pituitary adenomas and craniopharyngiomas. METHODS: Ten patients, nine with pituitary adenomas and one with a craniopharyngioma, underwent implantation of from two to eight Gliadel wafers. RESULTS: No obvious adverse reactions occurred. Death as a result of disease progression occurred in two patients with malignant adenomas. One patient died as a result of a stroke after undergoing five surgical procedures and prior radiotherapy. The seven living patients have been followed for 5 to 27 months (mean follow-up, 19 mo). Four patients have been free of recurrent or residual tumor, two have stable residual disease, and one has experienced tumor progression. CONCLUSION: The results of this study suggest a role for Gliadel implantation in patients with recurring aggressive pituitary adenomas and craniopharyngiomas.
Authors: Michael E Sughrue; Isaac Yang; Ari J Kane; Shanna Fang; Aaron J Clark; Derrick Aranda; Igor J Barani; Andrew T Parsa Journal: J Neurooncol Date: 2010-06-10 Impact factor: 4.130
Authors: Daniela A Bota; Annick Desjardins; Jennifer A Quinn; Mary L Affronti; Henry S Friedman Journal: Ther Clin Risk Manag Date: 2007-10 Impact factor: 2.423